Literature DB >> 35916943

Dynamic contrast-enhanced and diffusion-weighted MR imaging in early prediction of pathologic response to neoadjuvant chemotherapy in locally advanced gastric cancer.

Hai-Liang Li1, Jin-Rong Qu2, Jing Li3, Liang-Liang Yan3, Hong-Kai Zhang3, Yi Wang4, Shu-Ning Xu5.   

Abstract

PURPOSE: To investigate the efficacy of diffusion-weighted imaging (DWI) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for the early prediction of the pathologic response to neoadjuvant chemotherapy (NAC) in patients with locally advanced gastric cancer (LAGC).
METHODS: Fifty patients with LAGC who were treated with NAC followed by radical gastrectomy were enrolled. Uncontrasted and DCE-MRI were performed within 1 week before NAC. According to tumor regression grading (TRG), patients were labeled as responders (TRG = 0 + 1) and non-responders (TRG = 2 + 3). Apparent diffusion coefficients (ADC) and DCE-MRI kinetics (Ktrans, Ve, and Kep) were compared between the two groups. Logistic regression analysis was performed to screen independent factors to predict the NAC efficacy. The relationship between MRI parameters and TRG was studied by Spearman's correlation analysis. Receiver-operating characteristic curve analyses were applied to evaluate the efficacy.
RESULTS: ADC, Ktrans, and Kep values were higher in responders than in non-responders (p < 0.05) and correlated with TRG (p < 0.05). The ADC and Kep values were independent markers for predicting TRG. The area under the curve, sensitivities, specificities of ADC, Ktrans, Kep, and ADC + Kep were 0.813, 0.699, 0.709, 0.886;73.64%, 65.54%, 63.21%, 70.37%; 86.47%, 54.97%, 79.47%, 95.65%; respectively. ADC + Kep demonstrated a higher efficacy than Ktrans and Kep (p = 0.012, 0.011), but without improvement compared with ADC (p > 0.05).
CONCLUSION: Both DWI and DCE-MRI can effectively predict the pathologic response to NAC in LAGC. A combination of ADC and Kep increased the efficacy, and ADC is the most valuable imaging parameter.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Diffusion-weighted MR imaging; Dynamic contrast-enhanced MR imaging; Gastric cancer; Neoadjuvant chemotherapy; Treatment response

Mesh:

Substances:

Year:  2022        PMID: 35916943     DOI: 10.1007/s00261-022-03623-0

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  36 in total

1.  3T diffusion-weighted MRI in the response assessment of colorectal liver metastases after chemotherapy: Correlation between ADC value and histological tumour regression grading.

Authors:  Francescamaria Donati; Piero Boraschi; Federica Pacciardi; Rosa Cervelli; Maura Castagna; Lucio Urbani; Fabio Falaschi; Davide Caramella
Journal:  Eur J Radiol       Date:  2017-03-29       Impact factor: 3.528

2.  Cancer treatment and survivorship statistics, 2019.

Authors:  Kimberly D Miller; Leticia Nogueira; Angela B Mariotto; Julia H Rowland; K Robin Yabroff; Catherine M Alfano; Ahmedin Jemal; Joan L Kramer; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2019-06-11       Impact factor: 508.702

Review 3.  Multiparametric MRI as a potential surrogate endpoint for decision-making in early treatment response following concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma: a systematic review and meta-analysis.

Authors:  Chong Hyun Suh; Ho Sung Kim; Seung Chai Jung; Choong Gon Choi; Sang Joon Kim
Journal:  Eur Radiol       Date:  2018-01-26       Impact factor: 5.315

4.  The additive value of restaging-CT during neoadjuvant chemotherapy for gastric cancer.

Authors:  E C Gertsen; C de Jongh; H J F Brenkman; A C Mertens; I A M J Broeders; M Los; D Boerma; D Ten Bokkel Huinink; L van Leeuwen; F J Wessels; R van Hillegersberg; J P Ruurda
Journal:  Eur J Surg Oncol       Date:  2020-04-14       Impact factor: 4.424

5.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

6.  Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Jaffer A Ajani; Thomas A D'Amico; Khaldoun Almhanna; David J Bentrem; Joseph Chao; Prajnan Das; Crystal S Denlinger; Paul Fanta; Farhood Farjah; Charles S Fuchs; Hans Gerdes; Michael Gibson; Robert E Glasgow; James A Hayman; Steven Hochwald; Wayne L Hofstetter; David H Ilson; Dawn Jaroszewski; Kimberly L Johung; Rajesh N Keswani; Lawrence R Kleinberg; W Michael Korn; Stephen Leong; Catherine Linn; A Craig Lockhart; Quan P Ly; Mary F Mulcahy; Mark B Orringer; Kyle A Perry; George A Poultsides; Walter J Scott; Vivian E Strong; Mary Kay Washington; Benny Weksler; Christopher G Willett; Cameron D Wright; Debra Zelman; Nicole McMillian; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2016-10       Impact factor: 11.908

Review 7.  Predicting the response to chemotherapy in gastric adenocarcinoma: who benefits from neoadjuvant chemotherapy?

Authors:  William B Robb; Christophe Mariette
Journal:  Recent Results Cancer Res       Date:  2012

Review 8.  Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials.

Authors:  Federico Coccolini; Matteo Nardi; Giulia Montori; Marco Ceresoli; Andrea Celotti; Stefano Cascinu; Paola Fugazzola; Matteo Tomasoni; Olivier Glehen; Fausto Catena; Yutaka Yonemura; Luca Ansaloni
Journal:  Int J Surg       Date:  2018-02-20       Impact factor: 6.071

Review 9.  Comparison of neoadjuvant versus a surgery first approach for gastric and esophagogastric cancer.

Authors:  Maria C Russell
Journal:  J Surg Oncol       Date:  2016-08-11       Impact factor: 3.454

10.  18FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study.

Authors:  Paul M Schneider; Dilmurodjon Eshmuminov; Tamara Rordorf; Diana Vetter; Patrick Veit-Haibach; Achim Weber; Peter Bauerfeind; Panagiotis Samaras; Kuno Lehmann
Journal:  BMC Cancer       Date:  2018-05-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.